fashion -WSS

fashion

author：explore 2025-09-29 22:50:21 - browse：9713

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Clinic falsely told dozens they had Alzheimer's, suits say

leisure time

WSS

PEPFAR is under serious threat — and so is global health

My chronic pain journey would have been easier knowing 5 things % STAT

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

New Covid vaccine is recommended for everyone 6 months or older

Burning questions about Delta and the next phase of the Covid pandemic

Severe heat forecast: Where scorching temperatures will persist over the next week

knowledge

fashion

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA panel endorses Alnylam’s heart drug — after picking it apart

As demand for Covid shots wanes, Moderna seeks its next success

Malaysia cuts short music fest after British band slams anti

Continuity nursing helped my family in our darkest PICU moments

FDA panel endorses Alnylam’s heart drug — after picking it apart

State Dept. review finds Biden bears some blame for Afghanistan failures

Acelyrin, a rare IPO success, stumbles in its first big test

Cancer drug shortages should be causing more outrage

New requirements coming in 2024 for Americans traveling to Europe

explore

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Burning questions about Delta and the next phase of the Covid pandemic

What Henrietta Lacks's story taught me about my role as a doctor

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Telehealth for opioid use disorder is lifesaving

hotspot

hotspot

leisure time

hotspot